{
    "clinical_study": {
        "@rank": "35366", 
        "arm_group": {
            "arm_group_label": "Prostate cancer patients", 
            "arm_group_type": "Experimental", 
            "description": "Prostate cancer patients that have not responded to hormon therapy"
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Combining more than one drug may kill more tumor cells.\n\n      PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in\n      treating patients with metastatic recurrent prostate cancer that does not respond to hormone\n      therapy."
        }, 
        "brief_title": "Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Estimate the maximum tolerated dose of weekly intravenous doxorubicin (DOX)\n      that can be given in combination with oral estramustine (EM) in patients with metastatic\n      prostate cancer refractory to treatment with hormonal agents. II. Assess the frequency of\n      expression of the multidrug resistance phenotype in biopsy specimens from these patients.\n      III. Assess the response to DOX/EM in these patients.\n\n      OUTLINE: 2-Drug Combination Chemotherapy. Doxorubicin, DOX, NSC-123127; Estramustine, EM,\n      NSC-89199.\n\n      PROJECTED ACCRUAL: Three to 18 patients will be entered."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Biopsy proven metastatic prostate cancer Biopsy requirement\n        waived at principal investigator's discretion if new disease site technically inaccessible\n        and PSA elevated Recurrent disease following orchiectomy, estrogen, or\n        gonadotropin-releasing hormone agonist therapy If previously irradiated: Progressive\n        disease outside prior radiotherapy field required No brain metastases\n\n        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Hematopoietic:\n        Not specified Hepatic: Bilirubin no greater than 1.5 mg/dL ALT/AST less than 3 times\n        greater than normal Renal: Not specified Cardiovascular: Left ventricular ejection\n        fraction at least 45% No NYHA class III/IV status No unstable angina Other: No Crohn's\n        disease, ulcerative colitis, or other inflammatory bowel syndrome\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n        doxorubicin or estramustine Endocrine therapy: See Disease Characteristics At least 30\n        days since flutamide Estrogen or gonadotropin-releasing hormone agonists discontinued\n        prior to treatment Radiotherapy: At least 6 weeks since radiotherapy Surgery: Not\n        specified"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002721", 
            "org_study_id": "UNM-2394C", 
            "secondary_id": [
                "CDR0000064574", 
                "NCI-V96-0816"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Prostate cancer patients", 
                "intervention_name": "doxorubicin hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Prostate cancer patients", 
                "intervention_name": "estramustine phosphate sodium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Prostate cancer patients", 
                "intervention_name": "drug resistance inhibition treatment", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxorubicin", 
                "Estramustine", 
                "Sodium phosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "recurrent prostate cancer", 
        "lastchanged_date": "May 20, 2014", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/UNM-2394C"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Albuquerque", 
                    "country": "United States", 
                    "state": "New Mexico", 
                    "zip": "87131"
                }, 
                "name": "University of New Mexico Cancer Research & Treatment Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A PHASE I TRIAL OF ESTRAMUSTINE PHOSPHATE AND DOXORUBICIN IN HORMONE REFRACTORY METASTATIC PROSTATE CANCER", 
        "overall_official": {
            "affiliation": "University of New Mexico Cancer Center", 
            "last_name": "Anthony Y. Smith, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Respond to therapy", 
            "safety_issue": "Yes", 
            "time_frame": "six months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002721"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of New Mexico", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of New Mexico", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 1995", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }, 
    "geocoordinates": {
        "University of New Mexico Cancer Research & Treatment Center": "35.084 -106.651"
    }
}